CORT and gastrointestinal stromal tumor: Furthermore, SST2 was detected in 88%–100% of GI stromal tumors (GIST), and, also in this tumor entity, an association with favorable patient outcomes was demonstrated (Palmieri et al., 2007; Arne et al., 2013; Zhao et al., 2014).